EHS
EHS

Impressive Results With Lenvatinib in Challenging Tumors



(MedPage Today) — The multitargeted tyrosine kinase inhibitor (TKI) lenvatinib induced a strong tumor response in patients with previously treated advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), according to results from a phase…

Source link

EHS
Back to top button